For almost half of his life, Michael Murray has had to grapple with cancer, including multiple relapses. One of his hardest setbacks was hearing that his cancer had returned just weeks before he was set to start his freshman year at Boston College.
With the news, Murray worried that his future would be in jeopardy. Then, his care team at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center presented him with a plan that would allow him to settle into college life while also getting the best possible treatments.
“The way my Dana-Farber/Boston Children’s team listened to me and treated me made all the difference,” explains Murray, 20. “I was able to undergo treatment while still having fun and getting a chance to be a ‘normal college kid.’”
A surprising discovery
When Murray was 13 years old, he started experiencing terrible pain in his left knee. The athlete initially assumed he tore or tweaked something in his knee, and it took multiple trips to the doctor’s office before Murray underwent an MRI. The scan revealed a mass, and a biopsy confirmed it was cancer — specifically osteosarcoma, a type of bone cancer.
Murray underwent treatment in his hometown of Chicago, where he first needed chemotherapy to shrink the tumor before it could be surgically removed through a procedure known as limb-salvage surgery. The surgery preserves the limb by removing the part of the bone involved with the tumor and some of the tissues that surround it.
Following the original operation, Murray suffered a number of setbacks, triggering additional surgeries. Ultimately, Murray and his team elected to use part of his right fibula (the shorter of the two bones that make up the shin) to help reconstruct his left leg. The procedure was a success, and today Murray enjoys full mobility in both of his legs.
“The procedure allowed me to play sports again, and that was a huge mental boost,” Murray says.
After his surgery, Murray hit the ground running and was back playing sports. But a year after his diagnosis, his doctors found a spot in his lung, indicating that his cancer had spread. Murray would need to undergo surgery to remove this nodule.
“Hearing the cancer had returned was incredibly difficult because you think about all the progress you’ve made and how you’re going to have to start over,” says Murray. “I’ve had really difficult moments and difficult months, but I refuse to let the bad news get in the way of my recovery.”
The surgery was deemed successful, and there were no signs of cancer for the rest of Murray’s time in high school; he was even able to play baseball. Unfortunately, with less than a week to go before his move to Boston College, Murray had to confront a new reality: His cancer had returned a second time to the exact same location in his lung.
A new option
After consulting with his family and team in Chicago, Murray decided to go through with his move and transfer his care to Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. He was placed under the care of Katherine Janeway, MD, MMSc, senior physician at Dana-Farber/Boston Children’s and director of Clinical Genomics at Dana-Farber Cancer Institute.
Murray would need surgery again as well as additional treatment since he had already relapsed once. Rather than receive chemotherapy, both felt this was not the best course of action, Janeway proposed an alternative: a treatment plan including a post-surgery radiation and a new targeted cancer therapy, called a multi-targeted kinase inhibitor. Kinase inhibitors work by blocking particular enzymes (known as kinases) which help control certain cell functions, including metabolism, division, and survival. The goal of these drugs is to keep cancer cells from growing by blocking these cell functions, as well as the formation of new blood vessels in certain areas that tumors can use to grow.
Following the completion of this treatment, Murray has remained in remission for over a year.
As kinase inhibitors continue to show promising results for patients with relapsed osteosarcoma, like Murray, Dana-Farber/Boston Children’s has opened clinical trials to study how they could work with other drugs.
“There hasn’t been any significant progress in osteosarcoma in many years, but these clinical trials could help provide new options and outcomes for patients who desperately need them,” explains Janeway.
Celebrating each victory
Despite his setbacks, Murray considers himself lucky. Thanks to the flexibility he found at Dana-Farber/Boston Children’s, he’s been able to enjoy his college experience, and currently lives with the friends he made during his first week of school. His cancer journey has also led to an interest in orthopedics and sports medicine; Murray plans to enroll in medical school to pursue these passions following his college graduation.
Whether it’s playing softball with his friends, attending a Boston College tailgate, or just relaxing with his family, Murray has made it a habit to never take anything for granted.
“It’s OK to feel sad and down at times, but I’ve always tried to get through treatment with a smile on my face,” says Murray. “Every little victory is worth celebrating, and I’m lucky enough to be surrounded by the people I love.”